RxDoctor Payments Data

Karen Secor, PA

Medical · Newnan, GANPI 1437117280

Payments from drug & device makers

$9,295in general payments, 2019–2025

Across 482 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$858
  • Lilly USA, LLC$817
  • Xeris Pharmaceuticals, Inc.$663
  • AbbVie$654
  • Amgen$553
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$1752%
  • Food & beverage$9,12098%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,295 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$24,179
Medicare patients
108
Services billed
966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide220$300,723
JardianceEmpagliflozin238$272,985
MounjaroTirzepatide155$190,290
RybelsusSemaglutide62$92,323
TrulicityDulaglutide65$90,721
FarxigaDapagliflozin Propanediol67$73,727
Tresiba Flextouch U-200Insulin Degludec41$58,185
Tresiba Flextouch U-100Insulin Degludec66$44,253
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt25$30,259
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$27,994
Lantus SolostarInsulin Glargine,hum.Rec.Anlog130$20,903
Humalog Kwikpen U-200Insulin Lispro12$20,504
JanuviaSitagliptin Phosphate13$18,650
Fiasp FlextouchInsulin Aspart (Niacinamide)16$18,196
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/727$17,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,350$401,300300 claims
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog$817$298,286284 claims
Boehringer IngelheimJardiance$243$272,985238 claims
AstraZenecaFarxiga$206$73,72767 claims
MerckJanuvia$27$18,65013 claims
Sanofi-aventis U.S. LLCAdmelog$421$4,72313 claims
AbbVieSynthroid$654$2,58228 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$106$1,750218 claims
IBSA Pharma Inc.Tirosint$104$1,47611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.

Other medical in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →